Evidence map›Paper›PMID 28150186›Full record

Trial reportClinical research in cardiology : official journal of the German Cardiac Society2017

Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.

Gerasimos Filippatos, Dimitrios Farmakis, Marco Metra, Gad Cotter, Beth A Davison, G Michael Felker, Barry H Greenberg, Tsushung A Hua, Peter S Pang, Piotr Ponikowski and 4 more

Erratum issuedAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Trial
  2. Review
  3. Review
  4. Does rhythm matter in acute heart failure? An insight from the British Society for Heart Failure National Audit.Clinical research in cardiology : official journal of the German Cardiac Society · 2019
    Article
  5. Article
  6. Heart Disease and Relaxin: New Actions for an Old Hormone.Trends in endocrinology and metabolism: TEM · 2018
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Gerasimos FilippatosNational and Kapodistrian University of Athens, Medical School, Athens, Greece. geros@otenet.gr.
Dimitrios FarmakisNational and Kapodistrian University of Athens, Medical School, Athens, Greece.
Marco MetraUniversity of Brescia, Brescia, Italy.
Gad CotterMomentum Research Inc., Durham, NC, USA.
Beth A DavisonMomentum Research Inc., Durham, NC, USA.
G Michael FelkerDuke Clinical Research Institute, Durham, NC, USA.
Barry H GreenbergUniversity of California at San Diego, San Diego, CA, USA.
Tsushung A HuaNovartis Pharmaceuticals Corporation, New Hanover, NJ, USA.
Peter S PangIndiana University School of Medicine and Regenstrief Institute, Indianapolis, IN, USA.
Piotr PonikowskiClinical Military Hospital, Medical University, Wroclaw, Poland.
Min QianColumbia University, New York, NY, USA.
Thomas A SeverinNovartis Pharma AG, Basel, Switzerland.
Adriaan A VoorsUniversity of Groningen, Groningen, The Netherlands.
John R TeerlinkUniversity of California-San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAtrial fibrillation (AFib) is a common comorbidity in HF and affects patients' outcome. We sought to assess the effects of serelaxin in patients with and without AFib.

methodsIn a post hoc analysis of the RELAX-AHF trial, we compared the effects of serelaxin on efficacy end points, safety end points and biomarkers in 1161 patients with and without AFib on admission electrocardiogram.

resultsAFib was present in 41.3% of patients. Serelaxin had a similar effect in patients with and without AFib, including dyspnea relief by visual analog scale through day 5 [mean change in area under the curve, 541.11 (33.79, 1048.44), p = 0.0366 in AFib versus 361.80 (-63.30, 786.90), p = 0.0953 in non-AFib, interaction p = 0.5954] and all-cause death through day 180 [HR = 0.42 (0.23, 0.77), p = 0.0051 in AFib versus 0.90 (0.53, 1.52), p = 0.6888 in non-AFib, interaction p = 0.0643]. Serelaxin was similarly safe in the two groups and induced similar reductions in biomarkers of cardiac, renal and hepatic damage. Stroke occurred more frequently in AFib patients (2.8 vs. 0.8%, p = 0.0116) and there was a trend for lower stroke incidence in the serelaxin arm in AFib patients (odds ratios, 0.31, p = 0.0759 versus 3.88, p = 0.2255 in non-AFib, interaction p = 0.0518).

conclusionsSerelaxin was similarly safe and efficacious in improving short- and long-term outcomes and inducing organ protection in acute HF patients with and without AFib.

Indexed as

AgedAged, 80 and overAtrial FibrillationBiomarkersCardiovascular AgentsDyspneaElectrocardiographyFemaleHeart FailureHumansMaleMiddle AgedRecombinant ProteinsRelaxinStrokeTreatment OutcomeBiomarkersCardiovascular AgentsRecombinant ProteinsRelaxinserelaxin protein, humanAcute heart failureAtrial fibrillationRelaxinSerelaxin

Identifiers

PMID28150186
PMCPMC5511317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.